期刊文献+

PTEN甲基化及其异常表达与膀胱移行细胞癌的关系 被引量:3

下载PDF
导出
摘要 目的探讨PTEN基因启动子甲基化及其mRNA异常表达与膀胱移行细胞癌临床及病理特征的关系。方法应用甲基化特异性PCR(MSP)法检测膀胱移行细胞癌组织(48例)和正常膀胱组织(15例)PTEN基因启动子甲基化状态,应用RT-PCR技术检测其mRNA的表达水平。结果膀胱癌组织中PTEN启动子甲基化率为47.9%(23/48),而在15例正常膀胱组织中其启动子未发生甲基化,两组间差异具有统计学意义(P<0.01);PTEN基因mRNA在膀胱癌组织和正常膀胱组织中的阳性表达率分别是56.2%(27/48)和100.0%(15/15),两组间差异有统计学意义(P<0.01);PTEN基因启动子甲基化率与其mRNA表达水平在不同病理分级、临床分期间差异有统计学意义(P<0.05),且PTEN启动子甲基化与其mRNA表达存在明显关联性(χ2=21.372,r=0.555,P<0.01)。结论 PTEN基因启动子甲基化可导致其mRNA表达的缺失,对膀胱移行细胞癌的发生及转移有着极其重要的影响。
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第12期1249-1251,共3页 Journal of Third Military Medical University
基金 广东省医学科研基金(B2011368) 广东省科技计划项目(2010B06090042)
  • 相关文献

参考文献7

二级参考文献32

  • 1刘双林,张旭,吴准,李俊,李东,赵宇峰,马鑫.膀胱移行细胞癌中PTEN基因启动子甲基化及其表达的研究[J].中国现代医学杂志,2008,18(20):2939-2942. 被引量:5
  • 2Wan-Yee Lau,Eric C. H. Lai.Hepatocellular carcinoma: current management and recent advances[J].Hepatobiliary & Pancreatic Diseases International,2008,7(3):237-257. 被引量:102
  • 3ShengDing Bang-DongGong JianYu JunGu Hong-YuZhang Zu-BinShang QiFei PengWang Jing-DeZhu.Methylation profile of the promoter CpG islands of 14 “drug-resistance”genes in hepatocellular carcinoma[J].World Journal of Gastroenterology,2004,10(23):3433-3440. 被引量:14
  • 4孙昀,耿小平,朱立新,熊奇如,钱叶本,董桂银,李晓明.肝细胞癌中脆性组氨酸三联体基因的甲基化状况及其临床意义[J].中华外科杂志,2006,44(9):609-612. 被引量:13
  • 5Lin HH, Ke HL, Huang SP, et al. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E - cadherin, p16, p14, RASSF1A genes in urine [ J ]. Urol Oncol, 2009,30.
  • 6Kamijo T, Weber JD, Zambetti G, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 [ J]. Proc Natl Acad Sci, 1998,95 (14) :8292 - 8297.
  • 7Dominguez G, Silva J, Garcia JM, et al. Prevalence of aberrant methylation of plgARF over pl61NKda in some human primary tumors [ J]. Mutation Research, 2003,530(1/2) :9 - 17.
  • 8Orlow I, LaRue H, Osman I, et al. Deletions of the INK4A gene in superficial bladder tumors, association with recurrence[J]. Am J Pathol, 1999,155( 1 ) :105 - 113.
  • 9Dulaimi E, Hillinck J, de Caceres II, et al. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients [ J ]. Clin Cancer Res, 2004,10( 18 Pt 1 ) :6189 - 619334.
  • 10Kawamoto K, Enokida H, Gotanda T, et al. pl6INK4a and p14ARF methylation as a potential biomarker for human bladder cancerr[ J]. Biochemical and Biophysical Research Communications, 2006,339(3 ) : 790 - 796.

共引文献21

同被引文献35

  • 1吕庆杰,赵晓东,宋继谒,李晓晗,马颖,孟辉,姜卫国.卵巢癌PTEN基因失活机制的探讨[J].中华病理学杂志,2005,34(5):266-269. 被引量:15
  • 2Siegel R,Naishadham D,Jemal A. Cancer statistics,2013[J].{H}CA-A Cancer Journal for Clinicians,2013,(01):11-30.
  • 3Wang L,Lee 1 M,Zhang S M. Dietary intake of selected flavonols,flavones,and flavonoid-rich foods and risk of cancer in middleaged and older women[J].{H}American Journal of Clinical Nutrition,2009,(03):905-912.
  • 4Link A,Balaguer F,Goel A. Cancer chemoprevention by dietary polyphenols:promising role for epigenetics[J].{H}Biochemical Pharmacology,2010,(12):1771-1192.
  • 5Li Y,Chen H,Hardy T M. Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein[J].PLoS One,2013,(01):e54369.
  • 6Portela A,Esteller M. Epigenetic modifications and human disease[J].{H}Nature Biotechnology,2010,(10):1057-1068.
  • 7Rodriguez-Paredes M,Esteller M. Cancer epigenetics reaches mainstream oncology[J].{H}Nature Medicine,2011,(03):330-339.
  • 8Brait M,Sidransky D. Cancer epigenetics:above and beyond[J].Toxicol Mech Methods,2011,(04):275-288.
  • 9Jones P A,Baylin S B. The epigenomics of cancer[J].{H}CELL,2007,(04):683-692.
  • 10Cidado J,Park B H. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy[J].J Mammary Gland B iol Neoplasia,2012,(3/4):205-216.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部